U.S. market Closed. Opens in 15 hours 4 minutes

BCRX | BioCryst Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 7.03 - 7.44
52 Week Range 4.03 - 8.88
Beta 1.73
Implied Volatility 52.61%
IV Rank 8.69%
Day's Volume 4,070,544
Average Volume 1,964,884
Shares Outstanding 206,886,000
Market Cap 1,459,580,730
Sector Healthcare
Industry Biotechnology
IPO Date 1994-03-04
Valuation
Profitability
Growth
Health
P/E Ratio -11.57
Forward P/E Ratio N/A
EPS -0.61
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 536
Country USA
Website BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
*Chart delayed
Analyzing fundamentals for BCRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see BCRX Fundamentals page.

Watching at BCRX technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on BCRX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙